Category: Science

T1D Exchange

T1D Exchange and Sanofi Team Up For Study Of Diabetes Care in Young Patients

T1D Exchange, a non-profit organization focused on type 1 diabetes, and Sanofi have joined forces in the TEENs registry study, a study aimed at providing a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes and to deliver recommendations for better disease management and patients outcomes.
0 Shares
TRIALNET LOGO

Type 1 Diabetes TrialNet Prevention Study Open to Younger Children

Incidence of type 1 diabetes is increasing and the disease is presenting at earlier ages. Each year, in the U.S. alone, approximately 15,000 children and adolescents are diagnosed with type 1 diabetes. It is one of the most common chronic diseases in school-aged children.
0 Shares
Biodel logo

Biodel Receives NIH Grant to Develop Glucagon Formulations For Artificial Pancreas

The Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH) has awarded Biodel Inc. a grant for the development of novel and stable glucagon formulations for use in an artificial pancreas, also known as a closed loop pump system. The SBIR program is a highly competitive program that encourages domestic small businesses to engage in Federal Research/Research and Development that has the potential for commercialization.
0 Shares

An In-Depth Look at the Faustman Lab Research – Part 2

Faustman holds that BCG vaccination's primary role in this case is to induce TNF-a expression, and that TNF-a's primary role in this case is to kill the defective autoreactive T cells after they have developed, implying that treatment with BCG will only work with patients who are already diabetic. Faustman put her theory to the test and treated three long-term diabetics with BCG to see whether it would have any effect on their disease status.
0 Shares

TNF, BCG, and You and Me: An In-Depth Look at the Faustman Lab Research

And here’s where things get interesting for a cure-seeking diabetic: when scientists saw that cells were flooding islets with TNF-a, they decided to see what would happen if they changed the levels of TNF-a in mouse pancreases– and they found that changing the levels of TNF-a changes whether a mouse will get diabetes. Now take a guess: we have a blaring distress signal, TNF-a, that turns on all the cells of the adaptive immune system, and we have a disease that is characterized by adaptive immune cells overreacting and killing the body’s own cells...
0 Shares

Faustman Lab Research: How Excited Should You Be?

Last week, diabetes headlines were dominated by a new study from the Faustman Lab at Massachusetts General Hospital, published on Wednesday, August 8th on PLoS One, suggesting that a 90-year-old tuberculosis vaccine called BCG might hold promise for people living with type 1 diabetes. “Human Study Reignites Debate Over Controversial Diabetes ‘Cure,’” wrote Reuters. “Diabetes May Be Reversed By Long-Used Vaccine for TB,” proclaimed Bloomberg news.
0 Shares
mass General Hospital logo

Treatment With Generic Vaccine May Temporarily Reverse Type 1 Diabetes

A phase I clinical trial, led by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital (MGH) Immunobiology Laboratory, has confirmed that use of a generic vaccine to raise levels of an immune system modulator can cause the death of autoimmune cells targeting the insulin-secreting cells of the pancreas and temporarily restore insulin secretion in human patients with type 1 diabetes.
0 Shares

Immunomodulators for Treatment of Type 1 Diabetes: An Overview

In the 1980s, studies demonstrated that suppressing the immune system of people recently diagnosed with T1D reduced their insulin dependence and provided persuasive evidence that T1D is an autoimmune disease. “Back then it wasn't so clear,” says immunologist Jeffrey Bluestone of the University of California, San Francisco.
0 Shares